Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

Abstract: Described herein are innovations for classifying subtypes of DLBCL, as well as using the results of classification for diagnosis, prognosis, and therapy selection. In this way, the classifier can effectively classify subtypes of DLBCL and provide meaningful output for the benefit of medical practices and DLBCL patients. Also described are arrays and kits that can be used to measure expression of DLBCL signatures genes.

Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

Abstract: The present invention relates to isolated antibodies, or an antigen portions thereof, which bind to human HER3. The novel antibodies are of great utility since they allow for the sensitive and specific detection of human HER3. Detection of human HER3 is, e.g., possible in a tissue sample, even when such tissue sample is a formalin-fixed paraffin embedded tissue (FFPET) sample.

Abstract: Described herein are innovations for classifying subtypes of DLBCL, as well as using the results of classification for diagnosis, prognosis, and therapy selection. In this way, the classifier can effectively classify subtypes of DLBCL and provide meaningful output for the benefit of medical practices and DLBCL patients. Also described are arrays and kits that can be used to measure expression of DLBCL signatures genes.

Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

Abstract: Methods, kits, and systems for clarifying obfuscating pigments in histology samples such as an automated method of treating a histology sample with a clarifying reagent so that the clarifying reagent, contacts the sample and the pigments within the sample are decolorized , thus alleviating staining obfuscations associated with pigments. Decolorizing the pigments within the sample enables the histology sample to be interpretable by a qualified reader. An antigen retrieval step is performed after the clarification step.

Abstract: The present invention relates to isolated antibodies, or an antigen portions thereof, which bind to human HER3. The novel antibodies are of great utility since they allow for the sensitive and specific detection of human HER3. Detection of human HER3 is, e.g., possible in a tissue sample, even when such tissue sample is a formalin-fixed paraffin embedded tissue (FFPET) sample.

Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

Abstract: Methods, kits, and systems for clarifying biological samples containing obfuscating pigment are disclosed. An automated method of treating a sample mounted on a substrate to alleviate staining obfuscations associated with pigments within the sample includes applying a clarifying reagent so that the clarifying reagent contacts the sample and the pigments within the sample are decolorized. The pigments within the sample being decolorized enable the specifically stained sample to be interpretable by a qualified reader.

Abstract: Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and/or tissues, this region is inaccessible to the disclosed antigen-binding molecules. Thus, such antigen-binding molecules are useful at least to interrogate the regulated state of EGFR, predict the response of a cancer patient to EGFR inhibitor therapies, and/or predict the aggressiveness of neoplasms.

Abstract: Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and/or tissues, this region is inaccessible to the disclosed antigen-binding molecules. Thus, such antigen-binding molecules are useful at least to interrogate the regulated state of EGFR, predict the response of a cancer patient to EGFR inhibitor therapies, and/or predict the aggressiveness of neoplasms.

Abstract: Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and/or tissues, this region is inaccessible to the disclosed antigen-binding molecules. Thus, such antigen-binding molecules are useful at least to interrogate the regulated state of EGFR, predict the response of a cancer patient to EGFR inhibitor therapies, and/or predict the aggressiveness of neoplasms.

Abstract: The invention provides materials and methods for determining the aggressiveness of a cancer in a mammal. Specifically, the invention provides methods and methods for measuring the level of a TIEG marker in a sample. Such levels can be correlated with the aggressiveness of a cancer to predict patient outcome and develop treatment regimens.

Abstract: Methods to determine TIEF-1 polypeptide, or genetic rearrangements in the TIEF-1 gene, in a sample are provided. Also provided are TIEF-1 specific antibodies and nucleic acid probes, and methods of employing those antibodies and probes to detect breast cancer in situ in a mammalian tissue sample.

Abstract: A method of recovering colorectal epithelial cells or fragments thereof from a stool sample is provided. The method involves contacting a stool sample with a specific binding reagent having specificity for colorectal epithelial cells or membrane fragments thereof to form a complex containing the specific binding reagent and the colorectal epithelial cells or fragments thereof, and separating the complex from the sample. A method of detecting dysplastic colorectal epithelial cells or fragments thereof, wherein a specific binding reagent employed in the method has specificity for dysplastic colorectal epithelial cells or membrane fragments thereof, is also provided. An article of manufacture containing reagents for performing the method is further provided.